Doing now what patients need next
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in-vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Dedicated to improving the health and wellbeing of people in Australia
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty-one medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them antibiotics, antimalarials and cancer medicines. Roche has been recognised as the leading healthcare company in the Dow Jones Sustainability Indices for ten consecutive years.
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2018, employed more than 90,000 people worldwide. Roche invests around USD 11.4 billion each year in research and development worldwide, including over AUD 44 million in pharmaceuticals in Australia. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. Roche’s pharmaceutical division in Australia employs over 350 people who are dedicated to the clinical development, registration, sales, marketing and distribution of innovative pharmaceutical medicines. Australian patients have access to around 42 Roche medicines, and the company is the leading provider of cancer medicines in Australia by sales.
Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1 expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7-1 receptors. By inhibiting PD-L1, Tecentriq may enable the activation of T cells.
Tecentriq® (atezolizumab) + chemotherapy (carboplatin and etoposide) is now approved by the Therapeutic Goods Administration (TGA) for extensive-stage small cell lung cancer (ES-SCLC)
For more information, please visit www.roche-australia.com.
Roche Products Pty Limited
ABN: 70 000 132 865
Level 8, 30-34 Hickson Road
Sydney NSW 2000
(02) 9454 9000